Drugs / Autologous 3rd generation CD19-targeting CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02132624 | Apr 2014 → May 2017 | lymphoid leukemia, lymphoma | Uppsala University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous 3rd generation CD19-targeting CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02132624 ↗ |
| Modality | Cell therapy | “CAR T-cell therapy” PMID 34515338 ↗ Sep 2021 |
| Target | CD19 | “third-generation CAR T cells targeting CD19 to evaluate safety and efficacy” PMID 30097433 ↗ Aug 2018 |